

What is claimed is:

1) A method for delivering a pharmaceutical agent through a membrane, wherein the method comprises applying to said membrane a composition comprising:

- a) anionic phospholipids;
- b) a safe and effective amount of the pharmaceutical agent contained within the phospholipids; and
- c) a fusogenic protein or polypeptide derived from prosaposin

in a pharmaceutically acceptable carrier, wherein the concentration of the fusogenic protein or polypeptide is of a sufficient amount to deliver the pharmaceutical agent through the membrane.

10
2) The method of claim 2 wherein the concentration of phospholipids are in at least a 10-fold excess, by weight, to that of the fusogenic protein or polypeptide.

3) The method of claim 2 wherein the pH of the composition is between about 5.5 and 2.

4) The method of claim 3 wherein the anionic phospholipid is an anionic liposome.

5) The method of claim 4 wherein the fusogenic protein or polypeptide is associated with the liposome through an electrostatic and hydrophobic interaction.

6) The method of claim 5 wherein the membrane is selected from the group consisting of dermal and mucosal membranes.

- 7) The method of claim 1 wherein the fusogenic protein or polypeptide is selected from the group consisting of saposin A, saposin C, polypeptide analogs, derivatives, homologues, fragments of saposin A and saposin C, and mixtures thereof.
- 8) The method of claim 6 wherein the fusogenic protein or polypeptide is saposin C.
- 9) The method of claim 6 wherein the fusogenic protein or polypeptide is SEQ. ID. NO. 1.
- 10) The method of claim 6 wherein the fusogenic protein or polypeptide is SEQ. ID. NO. 2.
- 11) The method of claim 6 wherein the fusogenic protein or polypeptide is of the formula
- h-u-Cys-Glu-h-Cys-Glu-h-h-h-Lys-Glu-h-u-Lys-h-h-Asp-Asn-Asn-Lys-u-Glu-Lys-Glu-h-h-Asp-h-h-Asp-Lys-h-Cys-u-Lys-h-h,
- where h = hydrophobic amino acids, including, Val, Leu, Ile, Met, Pro, Phe, and Ala; and u = uncharged polar amino acids, including, Thr, Ser, Tyr, Gly, Gln, and Asn.
- 12) The method of claim 7 wherein administration of the composition is via a transdermal patch.
- 13) The method of claim 7 wherein the composition is administered either enterally or topically.
- 14) A method for delivering a pharmaceutical agent through either a dermal or mucosal membrane, wherein the method comprises the administration to said membrane of a composition comprising:

- 5 a) anionic liposo
 b) a safe and effective amount of the pharmaceutical agent contained within the
 liposomes; and
 c) saposin C;

10 in a pharmaceutically acceptable carrier, wherein the concentration of the liposomes are
 of a sufficient amount to deliver a safe and effective amount of the pharmaceutical agent
 through the membrane, the pH of the composition is between about 5.5 and 2, and the
 saposin C is associated with the surface of the liposome through an electrostatic and
 hydrophobic interaction.

15) The method of claim 14 wherein the concentration of the liposomes is in at least a 10-fold
 excess, by weight, to that of saposin C.

16) A therapeutic phospholipid composition comprising:

- a) an anionic phospholipid;
 b) a safe and effective amount of the pharmaceutical agent contained within the
 phospholipids; and
 c) a fusogenic protein or polypeptide derived from prosaposin;

10 in a pharmaceutically acceptable carrier, wherein the concentration of the fusogenic
 protein or polypeptide is present in a sufficient concentration to deliver the
 pharmaceutical agent through a biological membrane and the fusogenic protein or
 polypeptide is associated with the phospholipid through an electrostatic and hydrophobic
 interaction.

17) The phospholipid composition of claim 16 wherein the concentration of phospholipids is
 in at least a 10-fold excess, by weight, to that of the fusogenic protein or polypeptide.

- 18) The phospholipid composition of claim 17 wherein the pH of the composition is between about 5.5 and 2.
- 19) The phospholipid composition of claim 18 wherein the anionic phospholipid is an anionic liposome.
- 20) The phospholipid composition of claim 19 wherein the biological membrane is selected from the group consisting of dermal and mucosal membranes.
- 21) The phospholipid composition of claim 20 wherein the fusogenic protein or polypeptide is selected from the group consisting of saposin A, saposin C, polypeptide analogs, derivatives, homologues, fragments of saposin A and saposin C, and mixtures thereof.
- 22) The phospholipid composition of claim 20 wherein the fusogenic protein or polypeptide is saposin C.
- 23) The phospholipid composition of claim 20 wherein the fusogenic protein or polypeptide is SEQ. ID. NO. 1.
- 24) The phospholipid composition of claim 20 wherein the fusogenic protein or polypeptide is SEQ. ID. NO. 2.
- 25) The phospholipid composition of claim 20 wherein the fusogenic protein or polypeptide is of the formula

h h-u-Cys-Glu-[REDACTED]-Lys-Glu-h-h-h-Lys-Glu-h-u-Lys-h-h-Asn-Asn-Lys-u-Glu-

Lys-Glu-h-h-Asp-h-h-Asp-Lys-h-Cys-u-Lys-h-h,

5 where h = hydrophobic amino acids, including, Val, Leu, Ile, Met, Pro, Phe, and Ala; and u = uncharged polar amino acids, including, Thr, Ser, Tyr, Gly, Gln, and Asn.

26) The phospholipid composition of claim 21 wherein the composition is formulated as part of a transdermal patch.

27) The phospholipid composition of claim 21 wherein the composition is formulated for enteral or topical administration.

28) A therapeutic phospholipid composition used to deliver a pharmaceutical agent through either a dermal or mucosal membrane, wherein the composition comprises:

- a) anionic liposomes;
- b) a safe and effective amount of the pharmaceutical agent contained within the liposomes; and
- c) a fusogenic protein or polypeptide selected from the group consisting of saposin C, polypeptide analogs, derivatives, homologues, fragments of saposin C, and mixtures thereof;

10 in a pharmaceutically acceptable carrier where the pH of the composition is between about 5.5 and 2, wherein the concentration of the fusogenic protein or polypeptide is of a sufficient amount to deliver the pharmaceutical agent through a biological membrane and the fusogenic protein or polypeptide is associated with the surface of the liposome through an electrostatic and hydrophobic interaction.

29) The phospholipid composition of claim 28 wherein the concentration of the liposomes is in at least a 10-fold excess, by weight, to that of saposin C.

5

30) A composition comprising a safe and effective amount of a pharmaceutical agent contained in an anionic liposome, which is associated with a prosaposin-derived fusogenic protein or polypeptide via an electrostatic and hydrophobic interaction, wherein the concentration of the fusogenic protein or polypeptide is of a sufficient amount to deliver the pharmaceutical agent through a biological membrane, the composition contained in a pharmaceutically acceptable carrier, wherein the pH of the composition is between about 5.5 and 2.

F03E0205
F03E0206
F03E0207
F03E0208
F03E0209
F03E0210
F03E0211
F03E0212
F03E0213
F03E0214
F03E0215
F03E0216
F03E0217
F03E0218
F03E0219
F03E0220
F03E0221
F03E0222
F03E0223
F03E0224
F03E0225
F03E0226
F03E0227
F03E0228
F03E0229
F03E0230
F03E0231
F03E0232
F03E0233
F03E0234
F03E0235
F03E0236
F03E0237
F03E0238
F03E0239
F03E0240
F03E0241
F03E0242
F03E0243
F03E0244
F03E0245
F03E0246
F03E0247
F03E0248
F03E0249
F03E0250
F03E0251
F03E0252
F03E0253
F03E0254
F03E0255
F03E0256
F03E0257
F03E0258
F03E0259
F03E0260
F03E0261
F03E0262
F03E0263
F03E0264
F03E0265
F03E0266
F03E0267
F03E0268
F03E0269
F03E0270
F03E0271
F03E0272
F03E0273
F03E0274
F03E0275
F03E0276
F03E0277
F03E0278
F03E0279
F03E0280
F03E0281
F03E0282
F03E0283
F03E0284
F03E0285
F03E0286
F03E0287
F03E0288
F03E0289
F03E0290
F03E0291
F03E0292
F03E0293
F03E0294
F03E0295
F03E0296
F03E0297
F03E0298
F03E0299
F03E0201
F03E0202
F03E0203
F03E0204
F03E0205
F03E0206
F03E0207
F03E0208
F03E0209
F03E02010
F03E02011
F03E02012
F03E02013
F03E02014
F03E02015
F03E02016
F03E02017
F03E02018
F03E02019
F03E02020
F03E02021
F03E02022
F03E02023
F03E02024
F03E02025
F03E02026
F03E02027
F03E02028
F03E02029
F03E02030
F03E02031
F03E02032
F03E02033
F03E02034
F03E02035
F03E02036
F03E02037
F03E02038
F03E02039
F03E02040
F03E02041
F03E02042
F03E02043
F03E02044
F03E02045
F03E02046
F03E02047
F03E02048
F03E02049
F03E02050
F03E02051
F03E02052
F03E02053
F03E02054
F03E02055
F03E02056
F03E02057
F03E02058
F03E02059
F03E02060
F03E02061
F03E02062
F03E02063
F03E02064
F03E02065
F03E02066
F03E02067
F03E02068
F03E02069
F03E02070
F03E02071
F03E02072
F03E02073
F03E02074
F03E02075
F03E02076
F03E02077
F03E02078
F03E02079
F03E02080
F03E02081
F03E02082
F03E02083
F03E02084
F03E02085
F03E02086
F03E02087
F03E02088
F03E02089
F03E02090
F03E02091
F03E02092
F03E02093
F03E02094
F03E02095
F03E02096
F03E02097
F03E02098
F03E02099
F03E02100
F03E02101
F03E02102
F03E02103
F03E02104
F03E02105
F03E02106
F03E02107
F03E02108
F03E02109
F03E02110
F03E02111
F03E02112
F03E02113
F03E02114
F03E02115
F03E02116
F03E02117
F03E02118
F03E02119
F03E02120
F03E02121
F03E02122
F03E02123
F03E02124
F03E02125
F03E02126
F03E02127
F03E02128
F03E02129
F03E02130
F03E02131
F03E02132
F03E02133
F03E02134
F03E02135
F03E02136
F03E02137
F03E02138
F03E02139
F03E02140
F03E02141
F03E02142
F03E02143
F03E02144
F03E02145
F03E02146
F03E02147
F03E02148
F03E02149
F03E02150
F03E02151
F03E02152
F03E02153
F03E02154
F03E02155
F03E02156
F03E02157
F03E02158
F03E02159
F03E02160
F03E02161
F03E02162
F03E02163
F03E02164
F03E02165
F03E02166
F03E02167
F03E02168
F03E02169
F03E02170
F03E02171
F03E02172
F03E02173
F03E02174
F03E02175
F03E02176
F03E02177
F03E02178
F03E02179
F03E02180
F03E02181
F03E02182
F03E02183
F03E02184
F03E02185
F03E02186
F03E02187
F03E02188
F03E02189
F03E02190
F03E02191
F03E02192
F03E02193
F03E02194
F03E02195
F03E02196
F03E02197
F03E02198
F03E02199
F03E02200
F03E02201
F03E02202
F03E02203
F03E02204
F03E02205
F03E02206
F03E02207
F03E02208
F03E02209
F03E02210
F03E02211
F03E02212
F03E02213
F03E02214
F03E02215
F03E02216
F03E02217
F03E02218
F03E02219
F03E02220
F03E02221
F03E02222
F03E02223
F03E02224
F03E02225
F03E02226
F03E02227
F03E02228
F03E02229
F03E02230
F03E02231
F03E02232
F03E02233
F03E02234
F03E02235
F03E02236
F03E02237
F03E02238
F03E02239
F03E02240
F03E02241
F03E02242
F03E02243
F03E02244
F03E02245
F03E02246
F03E02247
F03E02248
F03E02249
F03E02250
F03E02251
F03E02252
F03E02253
F03E02254
F03E02255
F03E02256
F03E02257
F03E02258
F03E02259
F03E02260
F03E02261
F03E02262
F03E02263
F03E02264
F03E02265
F03E02266
F03E02267
F03E02268
F03E02269
F03E02270
F03E02271
F03E02272
F03E02273
F03E02274
F03E02275
F03E02276
F03E02277
F03E02278
F03E02279
F03E02280
F03E02281
F03E02282
F03E02283
F03E02284
F03E02285
F03E02286
F03E02287
F03E02288
F03E02289
F03E02290
F03E02291
F03E02292
F03E02293
F03E02294
F03E02295
F03E02296
F03E02297
F03E02298
F03E02299
F03E02200
F03E02201
F03E02202
F03E02203
F03E02204
F03E02205
F03E02206
F03E02207
F03E02208
F03E02209
F03E02210
F03E02211
F03E02212
F03E02213
F03E02214
F03E02215
F03E02216
F03E02217
F03E02218
F03E02219
F03E02220
F03E02221
F03E02222
F03E02223
F03E02224
F03E02225
F03E02226
F03E02227
F03E02228
F03E02229
F03E02230
F03E02231
F03E02232
F03E02233
F03E02234
F03E02235
F03E02236
F03E02237
F03E02238
F03E02239
F03E02240
F03E02241
F03E02242
F03E02243
F03E02244
F03E02245
F03E02246
F03E02247
F03E02248
F03E02249
F03E02250
F03E02251
F03E02252
F03E02253
F03E02254
F03E02255
F03E02256
F03E02257
F03E02258
F03E02259
F03E02260
F03E02261
F03E02262
F03E02263
F03E02264
F03E02265
F03E02266
F03E02267
F03E02268
F03E02269
F03E02270
F03E02271
F03E02272
F03E02273
F03E02274
F03E02275
F03E02276
F03E02277
F03E02278
F03E02279
F03E02280
F03E02281
F03E02282
F03E02283
F03E02284
F03E02285
F03E02286
F03E02287
F03E02288
F03E02289
F03E02290
F03E02291
F03E02292
F03E02293
F03E02294
F03E02295
F03E02296
F03E02297
F03E02298
F03E02299
F03E02200
F03E02201
F03E02202
F03E02203
F03E02204
F03E02205
F03E02206
F03E02207
F03E02208
F03E02209
F03E02210
F03E02211
F03E02212
F03E02213
F03E02214
F03E02215
F03E02216
F03E02217
F03E02218
F03E02219
F03E02220
F03E02221
F03E02222
F03E02223
F03E02224
F03E02225
F03E02226
F03E02227
F03E02228
F03E02229
F03E02230
F03E02231
F03E02232
F03E02233
F03E02234
F03E02235
F03E02236
F03E02237
F03E02238
F03E02239
F03E02240
F03E02241
F03E02242
F03E02243
F03E02244
F03E02245
F03E02246
F03E02247
F03E02248
F03E02249
F03E02250
F03E02251
F03E02252
F03E02253
F03E02254
F03E02255
F03E02256
F03E02257
F03E02258
F03E02259
F03E02260
F03E02261
F03E02262
F03E02263
F03E02264
F03E02265
F03E02266
F03E02267
F03E02268
F03E02269
F03E02270
F03E02271
F03E02272
F03E02273
F03E02274
F03E02275
F03E02276
F03E02277
F03E02278
F03E02279
F03E02280
F03E02281
F03E02282
F03E02283
F03E02284
F03E02285
F03E02286
F03E02287
F03E02288
F03E02289
F03E02290
F03E02291
F03E02292
F03E02293
F03E02294
F03E02295
F03E02296
F03E02297
F03E02298
F03E02299
F03E02200
F03E02201
F03E02202
F03E02203
F03E02204
F03E02205
F03E02206
F03E02207
F03E02208
F03E02209
F03E02210
F03E02211
F03E02212
F03E02213
F03E02214
F03E02215
F03E02216
F03E02217
F03E02218
F03E02219
F03E02220
F03E02221
F03E02222
F03E02223
F03E02224
F03E02225
F03E02226
F03E02227
F03E02228
F03E02229
F03E02230
F03E02231
F03E02232
F03E02233
F03E02234
F03E02235
F03E02236
F03E02237
F03E02238
F03E02239
F03E02240
F03E02241
F03E02242
F03E02243
F03E02244
F03E02245
F03E02246
F03E02247
F03E02248
F03E02249
F03E02250
F03E02251
F03E02252
F03E02253
F03E02254
F03E02255
F03E02256
F03E02257
F03E02258
F03E02259
F03E02260
F03E02261
F03E02262
F03E02263
F03E02264
F03E02265
F03E02266
F03E02267
F03E02268
F03E02269
F03E02270
F03E02271
F03E02272
F03E02273
F03E02274
F03E02275
F03E02276
F03E02277
F03E02278
F03E02279
F03E02280
F03E02281
F03E02282
F03E02283
F03E02284
F03E02285
F03E02286
F03E02287
F03E02288
F03E02289
F03E02290
F03E02291
F03E02292
F03E02293
F03E02294
F03E02295
F03E02296
F03E02297
F03E02298

36) The composition of claim 31 wherein the fusogenic protein or polypeptide is SEQ.ID.NO. 2.

37) The composition of claim 31 wherein the fusogenic protein or polypeptide is of the formula

h-u-Cys-Glu-h-Cys-Glu-h-h-h-Lys-Glu-h-u-Lys-h-h-Asp-Asn-Asn-Lys-u-Glu-
Lys-Glu-h-h-Asp-h-h-Asp-Lys-h-Cys-u-Lys-h-h,

5 where h = hydrophobic amino acids, including, Val, Leu, Ile, Met, Pro, Phe, and Ala; and
u = uncharged polar amino acids, including, Thr, Ser, Tyr, Gly, Gln, and Asn.

38) A phospholipid composition used to deliver a pharmaceutical agent through either a dermal or mucosal membrane, wherein the composition comprises:

- a) anionic liposomes;
- b) a safe and effective amount of the pharmaceutical agent contained within the liposomes; and
- c) saposin C;

in a pharmaceutically acceptable carrier, wherein the pH of the composition is between about 5.5 and 2, the concentration of the saposin C is of a sufficient amount to deliver the pharmaceutical agent through the membrane and the saposin C is associated with the surface of the liposome through an electrostatic and hydrophobic interaction.

10
39) The phospholipid composition of claim 38 wherein the concentration of the liposome is in at least a 10-fold excess, by weight, to that of saposin C.

40) The polypeptide of SEQ. ID. NO. 1.

41) The polypeptide of SEQ. ID. NO. 2.

42) A compound of the formula

h-u-Cys-Glu-h-Cys-Glu-h-h-h-Lys-Glu-h-u-Lys-h-h-Asp-Asn-Asn-Lys-u-Glu-Lys-Glu-h-h-Asp-h-h-Asp-Lys-h-Cys-u-Lys-h-h,

where h = hydrophobic amino acids, including, Val, Leu, Ile, Met, Pro, Phe, and Ala;

5 and u = uncharged polar amino acids, including, Thr, Ser, Tyr, Gly, Gln, and Asn.

43) A method for treating Gauchers Disease wherein the method comprises the administration of a composition comprising:

- a) anionic liposomes;
- b) a safe and effective amount of acid beta-glucosidase contained within the liposomes; and
- c) saposin C;

in a pharmaceutically acceptable carrier, wherein the pH of the composition between about 5.5 and 2, the concentration of the saposin C is of a sufficient amount to deliver the pharmaceutical agent through the membrane and the saposin C is associated with the surface of the liposome through an electrostatic and hydrophobic interaction.

10

44) The method of claim 43 wherein the concentration of the liposome is in at least a 10-fold excess, by weight, to that of saposin C.